193 related articles for article (PubMed ID: 21452927)
1. From targeted therapy in ovarian cancer to personalizing therapy for ovarian cancer.
Gómez-Raposo C; Mendiola M; Barriuso J; Hardisson D; Redondo A
Expert Opin Investig Drugs; 2011 May; 20(5):591-4. PubMed ID: 21452927
[TBL] [Abstract][Full Text] [Related]
2. Targeted Therapies for Ovarian Cancer.
Grunewald T; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():139-152. PubMed ID: 28111228
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
4. Personalising Treatment for High-Grade Serous Ovarian Carcinoma.
Cojocaru E; Parkinson CA; Brenton JD
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):515-524. PubMed ID: 29934103
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Ratner ES; Sartorelli AC; Lin ZP
Curr Opin Oncol; 2012 Sep; 24(5):564-71. PubMed ID: 22759740
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
Mukhopadhyay A; Curtin N; Plummer R; Edmondson RJ
BJOG; 2011 Mar; 118(4):429-32. PubMed ID: 21244617
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
8. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
Liu CH; Chang Y; Wang PH
Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
[No Abstract] [Full Text] [Related]
10. New developments in molecular targeted therapy of ovarian cancer.
Guan LY; Lu Y
Discov Med; 2018 Nov; 26(144):219-229. PubMed ID: 30695681
[TBL] [Abstract][Full Text] [Related]
11. Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
Veskimäe K; Staff S; Grönholm A; Pesu M; Laaksonen M; Nykter M; Isola J; Mäenpää J
Tumour Biol; 2016 Sep; 37(9):11991-11999. PubMed ID: 27155850
[TBL] [Abstract][Full Text] [Related]
12. Epithelial ovarian cancer: focus on targeted therapy.
Pliarchopoulou K; Pectasides D
Crit Rev Oncol Hematol; 2011 Jul; 79(1):17-23. PubMed ID: 20674385
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
14. The rise of genomic profiling in ovarian cancer.
Previs RA; Sood AK; Mills GB; Westin SN
Expert Rev Mol Diagn; 2016 Dec; 16(12):1337-1351. PubMed ID: 27828713
[TBL] [Abstract][Full Text] [Related]
15. [IV. Targeted therapies for epithelial ovarian cancer].
Mabuchi S; Sasano T; Kawano M; Kimura T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):193-8. PubMed ID: 24826387
[No Abstract] [Full Text] [Related]
16. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Scott CL; Swisher EM; Kaufmann SH
J Clin Oncol; 2015 Apr; 33(12):1397-406. PubMed ID: 25779564
[TBL] [Abstract][Full Text] [Related]
17. The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.
Al Bakir M; Gabra H
Br Med Bull; 2014 Dec; 112(1):57-69. PubMed ID: 25473022
[TBL] [Abstract][Full Text] [Related]
18. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
19. MMP-1-PAR1 axis mediates LPA-induced epithelial ovarian cancer (EOC) invasion.
Wang FQ; Fisher J; Fishman DA
Gynecol Oncol; 2011 Feb; 120(2):247-55. PubMed ID: 21093894
[TBL] [Abstract][Full Text] [Related]
20. [The molecular biology of epithelial ovarian cancer].
Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]